Connection

Solange Peters to Bevacizumab

Back to Details
This is a "connection" page, showing publications Solange Peters has written about Bevacizumab.
Solange Peters
Connection Strength
0.038
Bevacizumab
  1. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2017 05; 5(5):435-444.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.